Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116032 · ClinicalTrials.gov registry record
Immune Profiling for Cancer Immunotherapy Response
A clinical trial of Cancer and Hematologic Malignancy, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT06116032 is a study of Cancer and Hematologic Malignancy that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 1,500 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06116032, a study of Cancer and Hematologic Malignancy, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Methylation Cytometry
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2029-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06116032
The ClinicalTrials.gov registry entry for NCT06116032 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (57% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Methylation Cytometry is the first listed.
NCT06116032 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06116032 about?
NCT06116032 is a clinical study titled "Immune Profiling for Cancer Immunotherapy Response". In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
What is the current status of trial NCT06116032?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2022-10-03. Estimated completion is 2029-01-01.
What conditions does trial NCT06116032 study?
This clinical trial studies the following conditions: Cancer, Hematologic Malignancy, Blood Cancer, Tumor, Solid.
What interventions are being tested in trial NCT06116032?
The interventions under investigation include: Methylation Cytometry (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06116032?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116032 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.